ENDURING
SOLUTIONS.
enhance quality-of-life
enhance quality-of-life
Neuroview Technology is a data driven technology platform and medical device company focused on neurology outcomes. Our vision is to provide enduring solutions that enhance quality-of-life, improve clinical management and reduce cost of patient care.
REAL TIME DATA of the patient’s Neurological state with EEG.
Data is downloaded to patient’s SMART PHONE
CLOUD provides bidirectional information between the patient and care team.
DATA analytics provided for efficient clinician review
NEUROVIEW TECHNOLOGY'S breakthrough device is a small implantable subcutaneous long-term Brain monitor using EEG.
There are no long-term electroencephalography (EEG) monitor devices approved by the FDA. All EEG studies even if intensive are limited to no more than a few days providing very little information. However, all brain disorders are dynamic in nature changing over time. EEG has been in clinical use for many decades and has been utilized in vascular disease, Parkinson’s, psychiatric disorders, and mainly epilepsy.
Epilepsy affects almost 4 million adults and children in United States with up to 30% who do not effectively respond to medical therapy. To date, no reliable objective biometric measure for epilepsy and seizures exists. Physicians rely on subjective seizure reporting by patients and families which is 40-50% accurate. NEUROVIEW’S novel technology accurately identifies unrecognized seizures, prevents false characterization of events, and provides information to optimize management. Under treated or untreated seizures resulting from lack of accurate seizure recognition is associated with a poor quality of life, increases the risk of accidents and sudden death, and greatly contributes to the already high cost of epilepsy. This technology is the first long-term, minimally invasive device for EEG monitoring.
Data-driven decision-making (DDDM): data science, data analysis and intelligent programming are essential to achieve success in healthcare by democratizing and personalizing healthcare. Employing AI/ML/DDN to analyze long-term EEG data will create a comprehensive knowledge platform that is updated continuously with ongoing information and from other separate knowledge domains for personalized and group utilization by all stake holders. Improving outcomes, reducing costs, reducing time to optimum treatments, improving diagnostics, predicting outcomes, etc., is some of the anticipated personalized care that AI will bring to brain disorders.
After 30 years of treating patients with epilepsy including those undergoing epilepsy surgery, Neuroview Technology co-founders have designed this device to be easily implantable with a 15 minute minimally invasive same day surgery procedure under local anesthesia. The EEG data which it records is delivered to the cloud via smart device technology. Analytics and relevant information is available to the patient and physician 24 hours a day. This novel technology truly represents a paradigm shift in brain monitoring and the treatment of epilepsy and other neurologic disorders.
RUBEN KUZNIECKY, MD.
Learn More
Professor of Neurology and Vice-chair, academic affairs Northwell Health Hofstra University. Professor and former co-Director of NYU Epilepsy Center (2003-2017). Dr. Kuzniecky trained in Neurology and Epilepsy at the Montreal Neurological Institute. He is internationally known for his imaging work in epilepsy and for his work on malformations of cortical development and epilepsy and epilepsy genetics. Learn More
Werner Doyle, MD.
Learn More
Associate Professor in the Department of Neurosurgery at NYU and a member of the NYU Epilepsy center. He also has a degree in Mathematics. Dr. Doyle trained in Neurosurgery at NYU and Epilepsy surgery at Yale. He specializes in epilepsy surgery and collaborates with several labs in the NYU Neuroscience Institute, to study brain mechanisms, behavior and understanding the etiologic substrates of the brain that cause epilepsy.
Steven Pacia, MD
Learn More
Professor of Neurology and Vice Chair, Neurology, Northshore University Hospital, Northwell Health. Dr. Pacia trained in Neurology and Epilepsy at the Yale School of Medicine where he studied the first intracranial EEG validated classification for temporal lobe seizures. He served as the NYU site director for the only NIH funded multicenter study of Epilepsy Surgery prior to becoming Chief of Neurology at Lenox Hill Hospital
Daniel Friedman, MD
Learn More
Assistant Professor of Neurology and a member of the Comprehensive Epilepsy Center of at NYU. He received his medical degree from Case Western Reserve University, completed neurology residency at the Hospital of University of Pennsylvania and his epilepsy and EEG fellowships at Columbia University. He also has additional training in translational research. He is the co-director of the video-EEG laboratory at NYU Langone Medical Center
SCOTT VERNER
Learn More
Scott Verner is an accomplished healthcare executive with extensive leadership experience, including serving as CEO of TRIVIDIA Health, NIPRO Diagnostics Home Diagnostics (HDIX), and Applied Sciences Corporation. He has led multimillion-dollar R&D initiatives and driven innovation across highly automated medical device, chemical, and pharmaceutical manufacturing operations, resulting in measurable improvements in quality and cost efficiency. His career includes successful product launches in the medtech and pharmaceutical sectors with Novartis and Allergan. Scott brings deep expertise in growth strategy, licensing, mergers and acquisitions, fundraising, restructuring, and operations, positioning him as a valuable leader for global healthcare organizations in both public and private markets.
Louis Rauchenberger
Board Member
Learn More
Lou Rauchenberger has served in multiple senior management positions in his 30+ year career in the financial industry. At JP Morgan, his roles included being Chief Operating Officer responsible for overseeing Technology, Operations, Quantitative Research and Customer Service. In addition, Lou has served as Controller, Chief Compliance Officer and Chief Auditor. He has extensive experience in managing large-scale technology and control agendas and has long-standing experience in working within regulatory structures and processes. He holds a Bachelor of Arts degree from Fordham University. He serves on the Board of Directors of Covenant House, New York chapter.
JAMES KARWEL
Learn More
Jim joined NVT in July 2024 as CEO until January 2026 and will be joining the Board as CFO. He recently retired from Ernst & Young as a Partner in the Financial Services Organization of Ernst & Young LLP as the America’s Banking and Capital Markets (BCM) Leader. In his most recent role, he oversaw the markets strategy, clients, talent and overall business growth in this region. Jim has more than 40 years of experience building professional services businesses and advising Fortune 100 clients, government agencies, entrepreneurial startups, and JVs on successfully managing strategic global initiatives, including regulatory crisis, product development, innovation, and technology. Before joining EY, he worked at Robbins-Gioia, Inc., a large-scale strategic program management services firm and served the Government including U.S. Department of Defense, automotive, and telecommunications markets. He holds an MBA from the University of Dayton, and a B.S. in Mechanical Engineering from Drexel University. Jim currently serves on the board of Covenant House of New York as the vice-chairman.
RUBEN KUZNIECKY, MD.
Learn More
Professor of Neurology and Vice-chair, academic affairs Northwell Health Hofstra University. Professor and former co-Director of NYU Epilepsy Center (2003-2017). Dr. Kuzniecky trained in Neurology and Epilepsy at the Montreal Neurological Institute. He is internationally known for his imaging work in epilepsy and for his work on malformations of cortical development and epilepsy and epilepsy genetics. Learn More
Werner Doyle, MD.
Learn More
Associate Professor in the Department of Neurosurgery at NYU and a member of the NYU Epilepsy center. He also has a degree in Mathematics. Dr. Doyle trained in Neurosurgery at NYU and Epilepsy surgery at Yale. He specializes in epilepsy surgery and collaborates with several labs in the NYU Neuroscience Institute, to study brain mechanisms, behavior and understanding the etiologic substrates of the brain that cause epilepsy.
Steven Pacia, MD
Learn More
Professor of Neurology and Vice Chair, Neurology, Northshore University Hospital, Northwell Health. Dr. Pacia trained in Neurology and Epilepsy at the Yale School of Medicine where he studied the first intracranial EEG validated classification for temporal lobe seizures. He served as the NYU site director for the only NIH funded multicenter study of Epilepsy Surgery prior to becoming Chief of Neurology at Lenox Hill Hospital
Timir Datta
CTO Consultant
Learn More
Timir currently leads the Bioelectronics group at the Feinstein Institutes for Medical Research, Northwell Health, where he directs multidisciplinary programs focused on the development of next-generation implantable and biosensing systems. He brings over a decade of experience spanning custom ASIC development, implantable hardware, wireless telemetry, advanced packaging, and full system-level integration. At Neuroview, Timir is responsible for the development of the new technology platform, ensuring that foundational technical decisions support scalability, manufacturability, and downstream clinical and regulatory requirements. His approach emphasizes de-risking early design choices while maintaining flexibility for future product expansion. He holds a PhD in Electrical and Computer Engineering and has authored numerous peer-reviewed publications and patents in bioelectronics, neuromodulation, and implantable systems.
Gil Breiman
Legal Counsel
Learn More
Gil Breiman is a Partner at the law firm of Blank Rome LLP. Gil is actively involved with the innovation ecosystem, representing investors, entrepreneurs and corporations launching, growing, and exiting innovative businesses in a broad spectrum of high technology and life sciences fields. Gil serves as Co-Chair of the firm’s Venture Capital & Emerging Companies Group and as Chair of the firm’s international practice. Gil has been quoted and published articles in several publications and invited to speak at venture capital and emerging company conferences and academic settings on issues pertaining to entrepreneurship, investments and international business.
If you would like to learn more about Neuroview Technology, have a specific question, or would like to get in touch directly, please fill out the form below.